| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi |
| Completed | 3 | 400 | Europe | Fluticasone propionate/formoterol fumarate | SkyePharma AG | Asthma | 07/07 | 07/07 | | |
| Completed | 3 | 228 | Europe | FLUTIFORM® (Formoterol fumarate / Fluticasone propionate) | Mundipharma Research Limited | Asthma Bronchiale | 01/08 | 01/08 | | |
NCT00394199: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma |
|
|
| Completed | 3 | 357 | US, Canada | Fluticasone propionate/Formoterol Fumarate 100/10, Flutiform 100/10, Fluticasone propionate 100, Fluticasone 100, Formoterol fumarate 10, SKP Formoterol 10 | SkyePharma AG | Asthma | 02/08 | 02/08 | | |
| Completed | 3 | 211 | Europe, RoW | FLUTIFORM® (Formoterol fumarate / Fluticasone propionate) | Mundipharma Research Limited | Asthma | 02/08 | 02/08 | | |
NCT00393952: New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma |
|
|
| Completed | 3 | 557 | US | Fluticasone propionate/Formoterol fumarate 250/10, FlutiForm 250/10, Placebo, SKP Placebo, Fluticasone propionate/Formoterol fumarate 100/10, FlutiForm 100/10, Fluticasone propionate 250, Fluticasone 250, Formoterol fumarate 10, SKP Formoterol 10 | SkyePharma AG | Asthma | 04/08 | 04/08 | | |
NCT00393991: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma |
|
|
| Completed | 3 | 475 | US, Canada | Fluticasone propionate/formoterol fumarate 100/10, Flutiform 100/10, Fluticasone propionate 100, SKP Fluticasone 100, Formoterol fumarate 10, SKP Formoterol 10, Placebo, SKP Placebo | SkyePharma AG | Asthma | 04/08 | 04/08 | | |
NCT00563056 / 2007-001634-13: An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma |
|
|
| Completed | 3 | 227 | Europe | Flutiform, Flixotide plus Foradil | Mundipharma Research Limited | Asthma Bronchiale | 04/08 | 04/08 | | |
NCT00649025 / 2007-005653-37: A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults |
|
|
| Completed | 3 | 438 | US, Europe, RoW | FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA, Flovent | SkyePharma AG, Abbott, MDS Pharma Services | Asthma | 10/08 | 10/08 | | |
| Completed | 3 | 1667 | Europe | Flutiform 250/10 micrograms, Flutiform 50/5 micrograms, Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms, Flixotide pMDI 250 micrograms | Mundipharma Research Limited | Asthma, Bronchial | 06/09 | 10/09 | | |
NCT00747318: A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005 |
|
|
| Completed | 3 | 280 | US, Europe, RoW | SKP FlutiForm HFA pMDI, FlutiForm, fluticasone propionate/formoterol fumarate | SkyePharma AG, Abbott | Asthma | 05/10 | 06/10 | | |
NCT01099722 / 2009-017223-25: Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma |
|
|
| Completed | 3 | 261 | Europe, RoW | Flutiform, Symbicort Turbohaler | Mundipharma Research Limited | Asthma | 11/10 | 07/11 | | |
| Completed | 3 | 498 | Europe, RoW | Flutiform, Seretide, Flixotide | Mundipharma Research Limited | Asthma | 09/13 | 11/13 | | |
2014-004564-38: A study to compare how easily patients with breathing conditions (asthma, chronic obstructive pulmonary disease (COPD) and asthma COPD overlap syndrome) can use two different types of inhaler. |
|
|
| Completed | 3 | 368 | Europe | Fluticasone/formoterol BAI 50/5 µg, Fluticasone/formoterol BAI 125/5 µg, K-haler, Pressurised inhalation, suspension, Inhalation powder, flutiform® 50 micrograms / 5 micrograms per actuation pressurised inhalation, suspension, flutiform® 125 micrograms / 5 micrograms per actuation pressurised inhalation, suspension, Symbicort® Turbohaler® 100 micrograms/6 micrograms, Inhalation powder, Symbicort® Turbohaler® 200 micrograms/6 micrograms, Inhalation powder | Mundipharma Research Limited, Mundipharma Research Limited | Asthma, Asthma-COPD Overlap Syndrome (ACOS) and Chronic Obstructive Pulmonary Disease., Long term breathing problems (Asthma, Chronic Obstructive Pulmonary Disease and a combination of the two), Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT02753712 / 2015-000801-38: A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma |
|
|
| Completed | 3 | 105 | Europe, RoW | Fluticasone/Formoterol BAI, Fluticasone/Vilanterol DPI (Relvar Ellipta DPI) | Mundipharma Research Limited | Asthma | 08/17 | 08/17 | | |
NCT03387241: Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years |
|
|
| Unknown status | 3 | 330 | RoW | Fluticasone/ Formoterol, FLUTIFORM® pMDI (2 puffs bid), fluticasone/ salmeterol, Seretide® pMDI (2 puffs bid) | Mundipharma (China) Pharmaceutical Co. Ltd | Asthma | 12/19 | 03/20 | | |
SWIFT, NCT04124510: Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy |
|
|
| Terminated | 3 | 20 | RoW | Brand Name: Flutiform K-haler, Flutiform K-haler | Mundipharma Korea Ltd | Asthma | 09/20 | 09/20 | | |
